CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO JUNE 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, busi

CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO JUNE 2021

2 Forward-Looking Statements This presentation contains forward-looking statements about PDS

Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market

opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words "anticipates," "may," "can," "plans," "believes," "estimates," "expects," "projects," "intends,"

"likely," "will," "should," "to be," and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and

uncertainties that could cause actual results to differ materially from those anticipated.Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption "Risk Factors"

in the documents filed with the Securities and Exchange Commission ("SEC") from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue

reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included

in this presentation to reflect subsequent events or circumstances.

3 PDS Biotech's Versamune -based immunotherapies are designed to promote a powerful in vivo

tumor-specific CD8+ killer T-cell response Generate the right type and quantity of effective CD8+ killer T-cells Generate potency without systemic side effects Generate memory T-cells, to enhance durability of response A significant

barrier to effective immunotherapy has been the inability to promote adequate CD8+ killer T-cell responses in vivo resulting in diminished efficacy; 70-90% of cancer patients fail check point inhibitor therapy Versamune -based therapies also

show promising potential to:

PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on

the proprietary Versamune platform 4 NCI-initiated phase 2 combination trial of PDS0101 in advanced HPV-cancer reported strong potential clinical benefitNo new or elevated toxicities observed from the addition of PDS0101 to combination

therapyPre-clinical studies demonstrated potential to work with a wide array of oncogenes and viral antigensMultiple composition and application patents valid through mid-2030s Biopharma developing novel T-cell activating cancer treatment

candidates Three phase 2 oncology clinical trials in progress anticipated to release data in 2021Clinical partnerships with Merck, MD Anderson Cancer Center and National Cancer Institute~15 employees with headquarters in Florham Park, NJDebt

free with approximately $29.5M in cash* Pipeline Versamune Platform Corporate Overview *The Company received $4.5M from the sale of NJ Net Operating Loss Tax Benefits in May 2021 which has been added to the cash balance reported on our

Form 10-Q as of 3/31/2021.

PDS Biotech's robust Versamune -based pipeline is being developed in partnership with leaders in

immuno-oncology and infectious disease 5 Reference: Data on file. * *Consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquimica. Funding provided by The Ministry of Science, Technology and Innovation of Brazil ("MCTI")

PDS Biotech executive team has demonstrated success in the development and commercialization of leading

pharmaceutical products 6 Senior executive experience with management of strategy and execution at both large pharma and biotechsNotable drug development:Abelcet (Liposome Company/ Elan)PEG-Intron (Schering-Plough/ Merck) Frank

Bedu-Addo, PhDChief Executive Officer Co-founder>35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing Gregory Conn, PhDChief Scientific Officer >30 years of

translational clinical research experienceFormer Director of Clinical Research at National Cancer Institute Center for Cancer Research (Cancer Vaccine Branch) Lauren V. Wood, MDChief Medical Officer Senior executive experience with over 20

years of experience in high tech companiesIn-depth experience with M&A transactions, capital markets, business development and investor relations Seth Van Voorhees, PhDChief Financial Officer

Introduction to the Versamune Platform

Versamune is designed to induce a robust and targeted anti-tumor response in vivo when administered with

a tumor-associated antigen 8 References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202

(12): 3524-3536. Smalley Rumfield C et al. 2020. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. for ImmunoTherapy of Cancer 8:e000612. Promotes uptake of vaccine or immunotherapy and entry into lymph

nodes Promotes antigen processing and presentation to T-cells via MHC I and II pathways Activates Type I Interferon pathway, enabling a powerful anti-tumor killer CD8+ T-cell response Versamune + Tumor-associated proteins (antigens)

Greater quantity and quality of Versamune -induced killer T-cells may result in unique ability to

eradicate HPV-positive tumors after a single dose 9 Induced a >10-fold number of highly potent T-cells and eradication of HPV-positive tumors after a single dose in preclinical studies Single treatment dose Results typical of current

topclinical-stage HPV cancer vaccines Tumor rechallenge at Day 60; complete and sustained cure of cancer *Adjuvant = cytokine GM-CSFReferences: J. Immunology, 2019 (202), 1215; Studies in TC-1 tumor model with other immunotherapies

reported in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, September 25, 27 (42): 5906. (PDS0101)

PDS0101 Phase 2 Clinical Development

Combinations of PDS0101 with FDA-approved standard of careFirst line treatment of recurrent/metastatic

HPV-positive head and neck cancerCombination with KEYTRUDA Treatment of locally advanced cervical cancerCombination with chemoradiotherapy 11 Novel combinations of PDS0101 with promising, investigational immunotherapeutic agentsTreatment of

advanced HPV-associated cancers (anal, cervical, vaginal, head and neck etc.)Triple combination with Bintrafusp alpha (bi-functional checkpoint inhibitor - M7824) and M9241 (NHS-IL12 an antibody conjugated immuno-cytokine) Clinical strategy:

Develop PDS0101 in combination with established therapies for rapid proof-of-concept and risk mitigation

Phase 2 NCI-led clinical trial evaluating the triple combination of PDS0101, Bintrafusp alfa and M9241 in

advanced HPV-associated cancer 12 Indication Patients with advanced HPV-associated cancer who have failed prior treatment Clinical Agents Bintrafusp alfa: Bifunctional "trap" fusion proteinM9241: Antibody-conjugated immuno-cytokinePDS0101:

Versamune -based immunotherapy generating HPV-specific CD8+ T-cells Study goals Group 1: Objective response rate (ORR) in checkpoint inhibitor (CPI) na ve patientsGroup 2: ORR in patients who have failed checkpoint inhibitor therapy (CPI

refractory) Timing Full enrollment of 56 patientsComplete enrollment expected by Q4 2021/Q1 2022 Trial Sponsor The objective of this trial is to confirm that PDS0101 enhances the therapeutic benefit of Bintrafusp alfa and M9241 and may

lead to expanded evaluation in several pipeline products

13 Bintrafusp alfa (M7824 - bi-functional checkpoint inhibitor) Tumor Regression: 0/16 (0%)T-cell

Clones: 22 PDS0101 + Bintrafusp alfa + M9241 (NHS IL-12) Tumor Regression: 13/17 (76%)T-cell Clones: 3 *Reference: Smalley Rumfield C, Pellom ST, Morillon II YM, et al; Journal for ImmunoTherapy of Cancer 2020; 8:e000612. doi:

10.1136/jitc-2020-000612 Red - CD8+ (killer) T-cellsGreen - CD4 + (helper) T-cells T-cell clones per 25% of TCR repertoire (Average) Combination of PDS0101 with M9241 or Bintrafusp alfa generated superior targeted T-cell response; triple

combination demonstrated superior efficacy T-cell induction levels Preclinical study: Triple combination of PDS0101, Bintrafusp alfa (M7824) and M9241 (NHS-IL12) demonstrated higher targeted T-cell response

PDS0101 Phase 1 clinical trial: Powerful CD8+ T-cell response resulted in regression of CIN cervical

lesions & supported continued clinical studies 14 * When treated with selected human clinical trial dosage (1mg and 3mg Versamune )References: L. Wood et al. A Novel Enantio-Specific Cationic Lipid R-DOTAP + HPV16 E6 & E7 Antigens

Induces Potent Antigen-Specific CD8+ T Cell Responses In-Vivo in Subjects with CIN and High-Risk Human Papillomavirus Infection. Nov 8, 2019. SITC. Presentation O17. Most patients infected with multiple strains of HPV CIN lesion regression as

early as 1-3 months 60% 20% 20% Phase 1 trial results showed no serious or dose-limiting toxicities of PDS0101 monotherapy Monotherapy distinguished from key limitation of immuno-oncology: > 20-fold increase in circulating dual INF-

& Granzyme-b inducing killer T-cells vs. pre-treatment at day 14 led to rapid clearance of lesions*

PDS0101 is used in combination with other immunotherapies resulting in a multifunctional

therapy 15 Bintrafusp alfa exposes the tumor to attack and M9241 issues a signal calling T-cells to the tumor Reference: Smalley Rumfield C, Pellom ST, Morillon II YM, et al; Journal for ImmunoTherapy of Cancer 2020; 8:e000612. doi:

10.1136/jitc-2020-000612 Bintrafusp ALFA M9241 PDS0101 induces a powerful, HPV16-targeted CD8+ and CD4+ T-cell response PDS0101 Activated CD8+ killer T-cell Activated CD4+ helper T-cell The triple combination

works in synergy to prompt targeted T-cells to infiltrate and destroy the tumor TUMOR DESTROYED

Objective response rate is measured by RECIST 1.1 and represents at least a 30% reduction in tumor

sizeAdvanced HPV-related cancer that is checkpoint inhibitor na ve:Patients who fail chemotherapy and/or radiation progress to checkpoint inhibitor therapy12-24% ORR with standard of care checkpoint inhibitors30% ORR reported with experimental

monotherapy Bintrafusp alfa is the highest reported to dateAdvanced HPV-related cancer that is checkpoint inhibitor refractory:Few treatment options exist for these patients5-12% ORR reported with checkpoint inhibitors PDS0101 phase 2 triple

combination trial: Evaluated potential for superior preclinical tumor regression in advanced HPV-related cancer 16 A critical limitation of immunotherapy is the inability to induce large numbers of powerful tumor-attacking CD8+ (killer)

T-cells within the body, that can result in tumor reduction or elimination in a significant number of advanced cancer patients Reference: Strauss J, et al. J Immunother Cancer. 2020 Dec;8(2):e001395

Triple combination achieved 83% objective response among 6 HPV16-positive checkpoint inhibitor naive

patients, suggesting potential efficacy 17 Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of

Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients at a median of 8 months; numbers will change as more patients undergo evaluation

18 Triple combination shows promising durability in HPV16-positive checkpoint inhibitor na ve patients,

suggesting potential efficacy PDS0101 + Bintrafusp alfa + M9241 Standard of Care(Checkpoint Inhibitors) HPV16-positive Number of subjects 6 Ongoing responses at median of 8 months 80% (4/5)1 patient came off combination halting

response Survival at median of 8 months 100% (6/6) Historical is 7-11 months Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies.

Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. Preliminary results suggest PDS0101 induction of in vivo highly active tumor-attacking HPV16 killer (CD8+) T-cells that have the

potential for effective disease reduction and ongoing responses * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation

Triple combination achieved 58% tumor reduction among 12 HPV16 checkpoint inhibitor refractory

patients 19 Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual

Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients at a median of 8 months; numbers will change as more patients undergo evaluation 50% (2/4) recently added patients already have

ongoing tumor reduction but have not yet attained ORRTumor reduction is consistent with first 8 patients showing tumor reduction in 5/8

20 Triple combination shows promising durability in HPV16-positive checkpoint refractory

patients PDS0101 + Bintrafusp alfa + M9241HPV16 positive Standard of Care(Checkpoint Inhibitors) Number of patients 12 Number of patients with ongoing tumor reduction at a median of 8 months 86% (6/7) Number of patients with

ongoing objective response at a median of 8 months 80% (4/5)1 patient came off combination halting response Survival at median of 8 months 83% (10/12) Historical is 3-4 months Reference: Strauss J. et al. Phase II evaluation of the

triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect

data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation Preliminary results suggest PDS0101 induction of in vivo highly active tumor-attacking HPV16 killer (CD8+) T-cells even in extensively treated and

immunologically limited patients have the potential for effective disease reduction and ongoing responses

Results in seven (7) HPV16-negative patients suggests critical role of PDS0101-induced HPV16-specific

CD8+ T-cells in promoting tumor reduction 21 Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of

Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation Preliminary results suggest that

HPV16-specific CD8+ and CD4+ T-cell induction by PDS0101 as predicted by preclinical studies may promote enhanced clinical benefit of the triple combination

22 PDS Biotech-sponsored phase 2 trial evaluating the combination of PDS0101 and KEYTRUDA for first-line

treatment of HPV-associated metastatic/recurrent head and neck cancer (VERSATILE-002) Indication First line treatment of patients with HPV-associated head and neck cancer whose cancer has spread or returned Clinical Agents KEYTRUDA

(Standard of Care): Anti-PD1 checkpoint inhibitor (ORR ~20%)PDS0101: Versamune -based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Group 1: Objective response rate (ORR) in checkpoint inhibitor (CPI) na ve

patientsGroup 2: ORR in patients who have failed checkpoint inhibitor therapy (CPI refractory) Timing Preliminary data anticipated Q4 2021/Q1 2022: ORR minimum of 4 of 17 in CPI na ve and 2 of 21 in CPI refractory required for subsequent

stage 2 enrollment (n=95 patients) Trial Partner If achieved, confirmation that PDS0101 enhances the therapeutic benefit of checkpoint inhibitors could expand evaluation of Versamune -based therapies in multiple cancer indications

23 A Phase 2, investigator-initiated clinical trial evaluating PDS0101 in combination with

chemoradiation therapy in patients with locally advanced cervical cancer (IMMUNOCERV) Indication Treatment of patients with locally advanced cervical cancer - Stages IB3-IVA Clinical Agents Chemoradiotherapy (CRT - Standard of Care):

Cisplatin & radiation therapyPDS0101: Versamune -based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Safety, rate of regression and local control in patients with primary tumor 5cm (n=35

patients) Timing Preliminary data anticipated Q4 2021/1H 2022 - Rate of complete response by PET-CT at 6 months and rate of tumor volume reduction by MRI at 30-40 days from start of treatment Trial Sponsor If successful, this study could

support further investigation of Versamune -based immunotherapies in combination with chemotherapy or CRT to treat multiple cancers

Studies are designed to demonstrate efficacy and broad applicability of PDS0101 and the Versamune T-cell

activating platform 24 Potential to enhance anti-cancer efficacy of various cancer treatments: Combinations with checkpoint inhibitors, chemoradiotherapy and novel therapies may further demonstrate Versamune 's versatility. Broad potential

for additional partnerships: Successful phase 2 studies with PDS0101 could enable a broad pipeline of Versamune -based oncology products containing various antigens. Potential to treat all types of HPV-cancer: PDS0101 Phase 2 clinical studies

address multiple types of HPV-associated cancers. Potential applications beyond oncology: PDS0203 COVID-19 phase 1/2 trials may demonstrate protection and may induce durable T-cell responses against conserved regions of mutating viruses.

PDS0101 Near-Term Milestones and Market Opportunities